The 7 references without contexts in paper P. Rumyantsev O., П. Румянцев О. (2015) “РЕФРАКТЕРНОСТЬ ВЫСОКОДИФФЕРЕНЦИРОВАННОГО РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ К ЛЕЧЕНИЮ РАДИОАКТИВНЫМ ЙОДОМ // REFRACTORY OF WELL-DIFFERENTIATED THYROID CANCER TO THE TREATMENT WITH RADIOACTIVE IODINE” / spz:neicon:ogsh:y:2013:i:3:p:11-15

24
Carr L.L., Mankoff D.A., Goulart B.H. et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;21:5260–8.
(check this in PDF content)
25
Perez C.A., Santos E.S., Arango B.A. et al. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck 2012;5:736–45.
(check this in PDF content)
26
Kojic K.L., Kojic S.L., Wiseman S.M. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies. Expert Rev Anticancer Ther 2012;3:345–57.
(check this in PDF content)
27
Leboulleux S., Bastholt L., Krause T. et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;9: 897–905.
(check this in PDF content)
28
Gupta-Abramson V., Troxel A.B., Nellore A. et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;29:4714–9.
(check this in PDF content)
29
Hoftijzer H., Heemstra K.A., Morreau H. et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;6:923–31.
(check this in PDF content)
30
Kloos R.T., Ringel M.D., Knopp M.V. et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;10: 1675–84.
(check this in PDF content)